Mead Johnson Nutrition Co. (NYSE:MJN)‘s stock had its “outperform” rating reiterated by equities research analysts at BMO Capital Markets in a research note issued on Saturday. They presently have a $96.00 target price on the stock, down from their previous target price of $97.00. BMO Capital Markets’ price target points to a potential upside of 19.75% from the company’s current price.

Other research analysts have also issued reports about the stock. Citigroup Inc. boosted their price target on shares of Mead Johnson Nutrition from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, July 25th. Credit Suisse Group AG restated a “buy” rating and set a $96.00 price target on shares of Mead Johnson Nutrition in a research report on Thursday, June 30th. Societe Generale downgraded shares of Mead Johnson Nutrition from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $100.00 to $95.00 in a report on Friday, July 29th. Susquehanna reaffirmed a “hold” rating on shares of Mead Johnson Nutrition in a report on Thursday, June 16th. Finally, Zacks Investment Research downgraded shares of Mead Johnson Nutrition from a “buy” rating to a “hold” rating in a report on Monday, June 13th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $94.75.

Analyst Recommendations for Mead Johnson Nutrition (NYSE:MJN)

Shares of Mead Johnson Nutrition (NYSE:MJN) opened at 80.17 on Friday. The firm has a market capitalization of $14.80 billion, a P/E ratio of 30.16 and a beta of 1.26. Mead Johnson Nutrition has a one year low of $65.53 and a one year high of $94.40. The firm’s 50-day moving average price is $80.38 and its 200-day moving average price is $84.69.

Mead Johnson Nutrition (NYSE:MJN) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.10. The firm earned $941.50 million during the quarter, compared to analyst estimates of $967.25 million. Mead Johnson Nutrition had a net margin of 13.28% and a negative return on equity of 194.30%. The business’s revenue for the quarter was down 8.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.76 EPS. On average, equities analysts forecast that Mead Johnson Nutrition will post $3.48 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, October 3rd. Shareholders of record on Monday, September 19th were given a $0.4125 dividend. This represents a $1.65 dividend on an annualized basis and a dividend yield of 2.06%. The ex-dividend date was Thursday, September 15th. Mead Johnson Nutrition’s payout ratio is 62.03%.

In other Mead Johnson Nutrition news, Director Kimberly A. Casiano sold 710 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $89.75, for a total value of $63,722.50. Following the sale, the director now owns 7,110 shares in the company, valued at $638,122.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Graciela Monteagudo sold 45,873 shares of the company’s stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $87.64, for a total transaction of $4,020,309.72. Following the completion of the sale, the senior vice president now owns 13,800 shares in the company, valued at approximately $1,209,432. The disclosure for this sale can be found here. 0.50% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in MJN. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Mead Johnson Nutrition by 11.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,287 shares of the company’s stock worth $118,000 after buying an additional 131 shares during the period. Pinkerton Retirement Specialists LLC acquired a new stake in shares of Mead Johnson Nutrition during the second quarter worth $128,000. Checchi Capital Advisers LLC boosted its stake in shares of Mead Johnson Nutrition by 2.5% in the second quarter. Checchi Capital Advisers LLC now owns 1,418 shares of the company’s stock worth $129,000 after buying an additional 35 shares during the period. Feltz Wealth PLAN Inc. acquired a new stake in shares of Mead Johnson Nutrition during the second quarter worth $180,000. Finally, Ingalls & Snyder LLC acquired a new stake in shares of Mead Johnson Nutrition during the second quarter worth $214,000. Institutional investors and hedge funds own 96.93% of the company’s stock.

Mead Johnson Nutrition Company Profile

Mead Johnson Nutrition Company (Mead Johnson) is a pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, children’s nutrition and other nutritional products. The Company operates through three segments: Asia, North America/Europe and Latin America. Its product portfolio includes routine and specialty infant formulas, children’s milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders.

5 Day Chart for NYSE:MJN

Receive News & Stock Ratings for Mead Johnson Nutrition Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mead Johnson Nutrition Co. and related stocks with our FREE daily email newsletter.